Yes, Verve Therapeutics, Inc. is a publicly traded clinical-stage biotechnology company. It is listed on the Nasdaq Global Market under the ticker symbol VERV. The enterprise focuses on developing genetic medicines for cardiovascular diseases, giving public shareholders access to its cutting-edge gene-editing research and clinical pipeline developments.